A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 38 (6) , 603.e1-603.e7
Abstract
No abstract availableKeywords
Funding Information
- Canadian Urological Association
This publication has 25 references indexed in Scilit:
- Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical TrialEuropean Urology Oncology, 2018
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2017
- Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder CancerTranslational Oncology, 2017
- Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Noninvasive Diagnosis and Prognosis of Bladder Cancer: A 2-Center Prospective StudyJournal of Urology, 2013
- Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and PerspectivesEuropean Urology, 2013
- DNA methylation-based biomarkers in bladder cancerNature Reviews Urology, 2013
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Urine Markers for Detection and Surveillance of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2011
- Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2011
- Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell CarcinomaJournal of Clinical Oncology, 2005